Protein-loaded poly(ε-caprolactone) microparticles. II. Muramyl dipeptide for oral controlled release of adjuvant

Journal of Microencapsulation

Volumn 16, Issue 5, 1999, Pages 601-612

  Youan, B B C ^a   Benoit, M A ^a   Rollmann, B ^a   Riveau, G ^b   Gillard, J ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b Unité de Chimie Analytique ^*

Author keywords

Microencapsulation; Microparticles; Muramyl dipeptide; Oral immunization; Poly( caprolactone)

Indexed keywords

ADJUVANT; BOVINE SERUM ALBUMIN; MURAMYL DIPEPTIDE; POLYCAPROLACTONE; PROTEIN; SOLVENT;

ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CRYSTALLIZATION; DRUG RELEASE; EVAPORATION; HYDROPHOBICITY; IMMUNIZATION; MICROENCAPSULATION; PARTICLE SIZE; STOMACH JUICE;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; HEAT; PARTICLE SIZE; POLYESTERS; SERUM ALBUMIN, BOVINE; SOLVENTS; SURFACE PROPERTIES; VOLATILIZATION; WATER;

EID: 0032799816     PISSN: 02652048     EISSN: None     Source Type: Journal    
DOI: 10.1080/026520499288799     Document Type: Article

References (24)

1. CHAN, T. W., and BECKER, A., 1988, Formulation of vaccine adjuvant muramyldipeptides (MDP). 1. Characterization of amorphous and crystalline forms of a muramyldipeptide analogue. Pharmaceutical Research, 5, 523-527.
2. CHEDID, L., AUDIBERT, F., LEFRANCIER, P. CHOAY, J., and LEDERER, E., 1976, Modulation of the immune response by a synthetic adjuvant and analogues. Proceedings of the National Academy of Sciences (USA), 73, 2472-2475.
3. CRESCENZI, V., MANZINI, G., CALZOLAVI, G., and BORRI, C., 1972, Thermodynamics of fusion of poly-beta-propiolactone and poly(ε-caprolactone). Comparative analysis of the melting of aliphatic polylactone and polyesters chains. European Polymer Journal, 8, 449-463.
4. ELDRIDGE, J. H., HAMMOND, C. J., MEULBROEK, J. A., STAAS, J. K., GILLEY, R. M., and TICE, T. R., 1990, Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Pever's patches. Journal of Controlled Release, 11, 205-214.
5. ELLOUZ, F., ADAM, A., CIORBARU, R., and LEDERER, E, 1974, Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochemical and Biophysical Research Communications, 59, 1317-1325.
6. FIDLER, I. J., FAX, D., and ICHINOSE, Y., 1988, Potent in-situ activation of murine lung macrophages and therapy of melanoma metastases by the systemic administration of muramyltripeptide phosphatidylethanoamine and interferon gamma. Invasion Metastases, 9, 95-98.
7. FIDLER, I. J., SONE, S., FOGLER, W. E., and BARNES, Z. L., 1981, Eradication of spontaneous metastases and activation of alveolar rnacrophages by intravenous injection of lipcsomes containing muramyl dipeptide. Proceedings of the National Academy of Sciences (USA), 78, 1680-1684.
8. HALLS, T. D. J., RAJU, M. S., WENKERT, E., ZUBER, M., LEFRANCIER, O., and LEDERER, E., 1980, The anomeric configuration of the immunostimulant N-acetylmuramyldipeptide and some of its derivatives. Carbohydrate Research, 81, 173-176.
9. HORA, M. S., RANA, R. K., NUNBERG, J. H., TICE, T. R., GILEEY, R. M., and HUDSON, M. E., 1990, Release of human serum albumin from poly(lactide-co-glycolide) microspheres. Pharmaceutical Research, 7, 1190-1194.
10. LIDGATE, D. M., and BYERS, N. E., 1995, Development of an emulsion-based muramyl dipeptide adjuvant formulation for vaccines. In Vaccines Design: The subunit and adjuvant approach, edited by M. F. Powell and M. J. Newman (New York: Plenum Press), pp. 313-324.
11. LOWRY, O. M., ROSEBROUGH, N. J., FARR, A. L., and RANDALL, R. J., 1951, Protein measurement with Folin phenol reagent. Journal of Biological Chemistry, 193, 265-275.
12. MARX, P. A., COMPANS, R. W., GETTIE, A., STAAS, J. K., GILLEY, R. M., MULUGAN, M. J., YAMSHCHIKOV, G. V., CHEN, D., and ELDRIDGE, J., 1993, Protection against vaginal SIV transmission with microencapsulated vaccine. Science, 28, 1323-1327.
13. MORIN, C., BARRATT, G., FESSI, H., DEVISSAGUET, J. P., and PUISIEUX, F., 1993, Biodegradable nanocapsules containing a lipophilic immunomodulator: drug retention and tolerance towards macrophages in vitro. Journal of Drug Targeting, 1, 157-164.
14. 14C-labelled) in the mouse. International Journal of Immunopharmacology, 1, 35-41.
15. PITT. C. G., 1990, Poly(ε-caprolactone) and its copolymers. In Biodegradable polymers as drug delivery systems, edited by M. Chasin and R. Langer (New York: Marcel Dekker), pp. 71-120.
16. POWELL. M. F., FOSTER, K. C., BECKER, A. R., and LEE, 1988, Formulation of vaccine adjuvant muramyldipeptides (MDP). 2. The thermal reactivity and pH of maximum stability of MDP compounds in aqueous solution. Pharmaceutical Research, 5, 528-532.
17. SPONTON, E., DROUIN, D., DELATTRE, J., PUISIEUX, F., TENU, J. P., YAPO, A., BARRATT, G., and PETIT, J. F., 1985, Design of sterile muramyldipeptide-containing oligolamellar liposomes suitable for i.v. injection. Effect of liposome size and lipid composition on their ability to render peritoneal macrophages antitumoral. International Journal of Pharmaceutics, 23, 299-313.
18. TABATA, Y., and IKADA, Y, 1987a, Activation of macrophage in vivo to acquire antitumor activity by a muramyl dipeptide derivative encapsulated in microspheres composed of lactide copolymer. Journal of Controlled Release, 6, 189-204.
19. TABATA, Y., and IKADA, Y., 1987b, Macrophage activation through phagocytosis of muramyl dipeptide encapsulated in gelatin microspheres. Journal of Pharmacy and Pharmacology, 39, 698-704.
20. TABATA, Y., and IKADA, Y., 1989, Protein precoating of polylactide microspheres containing a lipophilic immunopotentiator for enhancement of macrophage phagocytosis and activation. Pharmaceutical Research, 6, 296-301.
21. VOGEL, F. R., 1995, The role of adjuvants in retroviral vaccines. International Journal of Immunopharmacology, 17, 85-90.
22. YANG, D., PEYMAN, G. A., and TANG, L., 1996, Chemical modification of PCL and the effect on drug release rate. Proceedings CRS Conference on Advances in Controlled Delivery, Baltimore, 19-22 August, pp. 47-48.
23. YOUAN, B. B. C., BENOIT, M. A., BARAS, B., and GILLARD, J., 1996, Characterization and in vitro release of polycaprolactone microparticles containing bovine serum albumin. Journal de Phamacie de Belgique, 51, 123.
24. YOUAN, B. B. C., BENOIT, M.-A., BARAS, B., and GILLARD, J., 1999, Protein-loaded poly(ε-caprolactone) microparticles I. Optimization of the encapsulation by (water-in oil)-in water emulsion solvent evaporation. Journal of Microencapsulation, in press.